Two cases of severe esophageal ulcer caused by chemotherapy for breast cancer after particle beam therapy for esophageal cancer

Author(s):  
Masaya Uesato ◽  
◽  
Haruhito Sakata ◽  
Hisahiro Matsubara ◽  
◽  
...  

Background: Particle beam treatment for esophageal cancer can produce a better local therapeutic effect than can conventional radiotherapy. However, events that occur in the esophagus during or after the treatment of other cancers after that are unknown. Case summary: The first patient, a 64-year-old woman, had undergone heavy ion radiotherapy for esophageal cancer. Endoscopic submucosal dissection was performed for local residual tumor. Five years later, cancer was found in the right breast, and the patient underwent partial mastectomy and adjuvant chemotherapy. Six years after heavy ion radiotherapy, oral intake became difficult. A benign esophageal ulcer with circumferential stenosis was observed at the site of heavy particle irradiation. The second patient, a 63-year-old woman, had undergone proton therapy for esophageal cancer and photodynamic therapy for local residual tumor. Four years later, cancer was found in the left breast, and the patient underwent preoperative adjuvant chemotherapy, which reduced the size of the breast cancer. Oral intake became difficult 5 years after proton therapy. Endoscopy showed a benign esophageal ulcer with severe stenosis at the site of proton irradiation. Conclusion: After particle beam therapy for esophageal cancer, patients who undergo chemotherapy for other cancers may develop an esophageal ulcer. Keywords: Particle beam therapy; esophageal cancer; esophageal ulcer; breast cancer; chemotherapy

2004 ◽  
Vol 22 (12) ◽  
pp. 2294-2302 ◽  
Author(s):  
Eva Thomas ◽  
Frankie A. Holmes ◽  
Terry L. Smith ◽  
Aman U. Buzdar ◽  
Debra K. Frye ◽  
...  

Purpose To evaluate the use of an alternate, non–cross-resistant adjuvant chemotherapy regimen in women with a poor pathologic response to a preoperative doxorubicin-based regimen. Patients and Methods Patients with locally advanced breast cancer received three cycles of vincristine, doxorubicin, cyclophosphamide, and prednisone (VACP) every 21 days followed by surgery. Patients with less than 1 cm3 residual tumor at mastectomy received an additional five cycles of VACP. Those with more than 1 cm3 residual tumor were randomly assigned to receive an additional five cycles of VACP or five cycles of vinblastine, methotrexate with calcium leucovorin rescue, and fluorouracil (VbMF). Results One hundred ninety-three patients were evaluable. Overall clinical response was seen in 83.4% after three cycles of VACP, whereas the pathologic complete response was 12.2%. One hundred six patients were randomly assigned to VACP or VbMF. Those receiving VbMF achieved higher relapse-free survival (RFS) and overall survival (OS) than those who received additional VACP, although the differences did not reach statistical significance. Initial stage of tumor, clinical complete response, and pathologic complete response were all associated with statistically superior survival rates. Conclusion Clinical and pathologic response to preoperative doxorubicin-based chemotherapy predicted for improved survival in women with operable breast cancer. For those with a poor response to initial neoadjuvant chemotherapy, treatment with VbMF was associated with a trend toward improved RFS and OS compared with those continuing with the doxorubicin regimen.


1989 ◽  
Vol 50 (C1) ◽  
pp. C1-629-C1-641
Author(s):  
Y. JONGEN

Sign in / Sign up

Export Citation Format

Share Document